Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib

Changhoon Yoo(Ulsan College), Jae‐Lyun Lee(Ulsan College), Cheolwon Suh(Ulsan College), Song Cheol Kim(Ulsan College), Jeong‐Eun Kim(Ulsan College), Jin‐Hee Ahn(Ulsan College), Tae Won Kim(Asan Medical Center), Shinkyo Yoon(Ulsan College)
Sarcoma
January 1, 2009
10.1155/2009/360875
Cited by 24

Related Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577